Literature DB >> 3139342

Modulation of Klebsiella pneumoniae infection of mice by interferon-gamma.

M J Hershman1, H C Polk, J D Pietsch, D Kuftinec, G Sonnenfeld.   

Abstract

The aim of this study was to determine the efficacy of interferon-gamma (IFN-gamma) as prophylaxis and therapy in a wound infection model with a 'surgical' pathogen. The bacterial challenge consisted of intramuscular injections of Klebsiella pneumoniae (10(3) organisms in 0.1 ml). Groups of 12 CBA/J mice had either IFN-gamma or RPMI-1640 medium (controls) injected subcutaneously. Mice pretreated with IFN-gamma in a dose of 7,500 or 750 units per day, followed by infection and 2 days additional IFN-gamma treatment, survived significantly longer than controls or mice treated with 150 units of IFN-gamma per day. Significantly greater survival than controls was seen with only 5 or 3 days pretreatment with IFN-gamma but not with 1 day pretreatment. Administration of IFN-gamma to the opposite hind leg from the one receiving bacterial challenge was as effective as same leg treatment. When IFN-gamma therapy was commenced 1 h after bacterial challenge and continued for 7 days, 13 of 60 mice survived, which was significantly greater than four of 60 surviving controls. These effects may be secondary to IFN-gamma's immunoregulatory effects rather than by involving any antiviral properties.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3139342      PMCID: PMC1541566     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  6 in total

1.  Nonspecific enhancement of host defenses against infection: experimental evidence of a new order of efficacy and safety.

Authors:  H C Polk; J H Calhoun; L D Lowrey; S P Blanchard; R J Brewer; S T Adams; L Chedid
Journal:  Surgery       Date:  1981-08       Impact factor: 3.982

2.  Effect of treatment with interferon-gamma and concanavalin A on the course of infection of mice with Salmonella typhimurium strain LT-2.

Authors:  C L Gould; G Sonnenfeld
Journal:  J Interferon Res       Date:  1987-06

3.  Recombinant gamma interferon is a potent adjuvant for a malaria vaccine in mice.

Authors:  J H Playfair; J B De Souza
Journal:  Clin Exp Immunol       Date:  1987-01       Impact factor: 4.330

4.  Mouse fibroblast interferon modifies Salmonella typhimurium infection in infant mice.

Authors:  G Bukholm; B P Berdal; C Haug; M Degré
Journal:  Infect Immun       Date:  1984-07       Impact factor: 3.441

5.  Effect of treatment of mice with sera containing gamma interferon on the course of infection with Salmonella typhimurium strain LT-2.

Authors:  Z Izadkhah; A D Mandel; G Sonnenfeld
Journal:  J Interferon Res       Date:  1980

6.  Biological activity of a new synthetic muramyl peptide adjuvant devoid of pyrogenicity.

Authors:  L A Chedid; M A Parant; F M Audibert; G J Riveau; F J Parant; E Lederer; J P Choay; P L Lefrancier
Journal:  Infect Immun       Date:  1982-02       Impact factor: 3.441

  6 in total
  5 in total

Review 1.  Animal models in interferon research: some current trends.

Authors:  H Schellekens
Journal:  Experientia       Date:  1989-06-15

2.  Interferon gamma in trauma-related infections.

Authors:  D J Dries
Journal:  Intensive Care Med       Date:  1996-10       Impact factor: 17.440

3.  Effect of in vivo administration of recombinant murine gamma interferon on in vitro lymphoproliferative responses following immunization with Candida albicans.

Authors:  R E Garner; U Kuruganti; L A al-Hussaini; C W Czarniecki; J E Domer
Journal:  Infect Immun       Date:  1992-05       Impact factor: 3.441

4.  Early decrease in surface expression of HLA-DQ predicts the development of infection in trauma patients.

Authors:  J V Taylor; L E Gordon; H C Polk
Journal:  Clin Exp Immunol       Date:  2000-12       Impact factor: 4.330

5.  Influence of acetylsalicylic acid on a Listeria monocytogenes infection.

Authors:  S Hockertz; I Paulini; K Rogalla; T Schettler
Journal:  Agents Actions       Date:  1993-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.